Expression of MCT1 and MCT4 were found to be upregulated in many cancer types, including breast cancer [72,73], colorectal cancer [74], glioblastoma [75,76], prostate cancer [77], clear cell renal cell carcinoma [78], and lung carcinomas [79]. Here, SLC16A1 is linked to breast cancer.